Join the Heart Failure group to help and get support from people like you.
Heart Failure News (Page 6)
Related terms: CHF
Quadriceps Strength Linked to Lower Risk for Heart Failure After AMI
FRIDAY, May 26, 2023 – A higher level of quadriceps isometric strength (QIS) is associated with a lower risk for developing heart failure after acute myocardial infarction (AMI), according to a...
Addition of GLP1-RA Tied to Lower MACE, Heart Failure Risk in Those With Diabetes
FRIDAY, May 12, 2023 – For individuals with diabetes without preexisting cardiovascular disease, the addition of glucagon-like peptide 1 receptor agonists (GLP1-RA) is associated with a lower risk...
Long-Term Air Pollution Exposure Tied to More Diagnostic Testing in Heart Failure
FRIDAY, May 5, 2023 – Long-term exposure to fine airborne particles
FDA Approves Furoscix (furosemide injection) for the At-Home Treatment of Congestion Due to Fluid Overload in Chronic Heart Failure
Furoscix demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) – scPharmaceuticals...
US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death ...
FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease
VIENNA, VA. (PRWEB) JUNE 21, 2021 Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company’s New Drug Application for Soaanz, a o...
Entresto Granted Expanded Indication in Chronic Heart Failure by FDA
EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to red...
FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a...
Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 – AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (...
FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes
21 October 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in...
FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure
East Hanover, N.J., Oct. 1, 2019 – Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart f...
Medicure Announces FDA Approval Received for Prexxartan (valsartan) Oral Solution
WINNIPEG, Dec. 19, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc. ("Carmel") has...
CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension
Farmville, NC. August 7, 2017 – CMP Pharma today announced that the US Food and Drug Administration (FDA) has granted final approval of the company’s New Drug Application (NDA) for CaroSpir (Sp...
FDA Approves Qbrelis (lisinopril) Oral Solution for Pediatric Patients 6 Years of Age and Older
Denver, July 29, 2016 — Silvergate Pharmaceuticals, Inc., leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food a...
FDA Approves Entresto (sacubitril/valsartan) for Heart Failure
July 7, 2015 – The U.S. Food and Drug Administration today approved Entresto (sacubitril/valsartan) tablets for the treatment of heart failure. The drug has been shown to reduce the rate of...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Left Ventricular Dysfunction, Cardiovascular Conditions and Disorders
Related drug support groups
lisinopril, metoprolol, warfarin, Coumadin, spironolactone, triamcinolone, Metoprolol Succinate ER, carvedilol, diltiazem, view more... Lasix, Entresto, furosemide, bisoprolol, valsartan, Farxiga, Jardiance, ramipril, digoxin, prazosin, Diovan, nitroglycerin, Coreg